Stites and Harbison's Biotechnology/Life Sciences Law Group includes highly experienced and dedicated attorneys focused on intellectual property protection of all aspects of biotechnology and life sciences. These include genetic engineering, immunology, monoclonal antibodies, medical devices, diagnostics, therapeutics, genetic markers, and pharmaceuticals.
The Intellectual Property (IP) members of the Biotechnology/Life Sciences Law Group have extensive backgrounds in biotechnology and related fields, including work in research laboratories, experience with Patent Examination for the USPTO, and advanced degrees, and/or technical experience in fields such as microbiology and immunology, biology, and pharmacology and cell biophysics.
The Biotechnology/Life Sciences Law Group represents a full range of clients in the biotechnological arts, ranging from major companies and universities through a number of smaller start-up businesses.
In addition to patent prosecution, the Biotechnology/Life Sciences group counsels clients on all matters relating to domestic and international intellectual property issues. This includes issues relating to infringement, validity, and freedom to operate. Our group also has deep experience in litigation, and has handled cases involving biotechnological inventions in both federal and state courts.
Stites & Harbison distinguishes itself by having ongoing relationships with intellectual property firms throughout the world. This gives our clients access to highly skilled international intellectual property counsel wherever and whenever needed.
In addition to offices in the major Southeastern cities of Atlanta, Louisville, and Nashville, our strategically located office in Alexandria, Virginia, allows Stites & Harbison attorneys to have in-person visits with Patent Examiners at the United States Patent & Trademark Office to discuss cases and advance our clients' positions.
Examples of recent biotechnology/life sciences patents issued with Stites & Harbison patent attorneys as counsel include the following:
- 10,047,171 – Amphiphilic bioconjugates obtained from xylan derivatives
- 10,046,009 – Method of treatment using a pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and its cofactor
- 10,045,966 – Compositions and methods for treating microbial infections
- 10,041,956 – Methods and kits for predicting a response to an erythropoietic agent
- 10,036,068 – Diagnosis, prognosis, and treatment of myocardial infarction
- 10,016,510 – Immunogenic composition in emulsion form
- 10,005,792 – Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
- 10,000,545 – CD147 as receptor for pilus-mediated adhesion of Meningococci to vascular endothelia
- 9,994,509 – Inhibitors of viral replication, their process of preparation and their therapeutical uses
- 9,980,945 – Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
- 9,975,945 – Passive immunisation against influenza, in particular H5N1
- 9,974,779 – Piperidine derivatives as human papilloma virus inhibitors
- 9,968,673 – Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
- 9,968,663 – Erythrocytes containing arginine deiminase
- 9,963,466 – Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists
- 9,956,231 – Topical formulations comprising a steroid
- 9,950,049 – Composition and therapeutic anti-tumour vaccine
- 9,949,990 – Oral composition of celecoxib for treatment of pain
- 9,915,662 – Protein microarray for characterizing the specificity of the monoclonal immunoglobulins of MGUS or myeloma patients
- 9,908,858 – Method for the synthesis of a hydrazine that can be used in the treatment of the papilloma virus
- 9,895,439 – Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
- 9,879,043 – Synthesis of non-natural cofactor analogs of S-adenosyl-L-methionine using methionine adenosyltransferase
- 9,868,770 – Recombinant Der P 2 expressed in Pichia Pastoris as a "natural-like" allergen for immunotherapy and diagnostic purposes
- 9,867,879 – Methods for use of small molecule activators of hem-Y / protoporphyrinogen oxidase (PPO)
- 9,856,252 – 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase
- 9,714,434 – Vector particles for targeting CD34+ cells
- 9,713,601 – Ingenol derivative compounds and methods useful for inhibiting cancer cell viability and treating cancer
Biotechnology/Life Sciences is part of Stites & Harbison's larger, Intellectual Property and Technology (IPT) group, which includes more than 20 attorneys – many of whom are Registered U.S. Patent Attorneys – with experience spanning all technical disciplines. Our IPT group uses a team approach to provide clients with comprehensive intellectual property services. Our attorneys practice throughout the nation and the world in the areas of patents, trademarks, copyrights, trade secrets, licensing, computer software, e-commerce and intellectual property litigation.
Time: 8:00 a.m. - 4:00 p.m.
Intellectual Property attorney Nick Stewart will present at this Webinar for Kentucky Engineering Law on August 31, 2020.
LOUISVILLE, Ky.—Managing Intellectual Property magazine has named seven Stites & Harbison, PLLC attorneys to the 2020 “IP Stars” list. The publication recognizes the most highly regarded intellectual property attorneys in the U.S.
LOUISVILLE, Ky.—Chambers USA selected 19 Stites & Harbison, PLLC attorneys in Kentucky and Tennessee for inclusion in their 2020 guide.
As more states begin legalizing marijuana, there remains substantial tension with federal law, under which marijuana is illegal.